MAPK

SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.

Cobimetinib racemate (Cobimetinib (racemate)) (GDC-0973 racemate) is a selective inhibitor of MEK.Cobimetinib racemate is also known as a mitogen-activated

3344 is an inhibitor of KRAS-effector interactions,with an affnity of 126nm.

Samidin has anti-inflammatory properties through suppression of NF-κB and AP-1-mediated-genes in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.

KRAS inhibitor-6 is a potent KRAS G12C inhibitor.

KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].

Asperulosidic acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities. ASPA is related to the inhibition of inflammatory cytokines.

10-Ethenyl-19-norprogesterone (Org OD 02-0) is a selective agonist for the membrane progesterone receptor α (mPRα) with an IC50 of 33.9 nM, known to activate

GNE-1858 inhibits HPK1; IC50: 1.9 nM for wild-type, 1.9 nM (HPK1-TSEE), 4.5 nM (HPK1-SA).

Broussonin E could suppress inflammation by modulating macrophages activation state via inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway, and can be further developed as a promising drug for the treatment of inflammation-related

KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .

ASP2453 is a potent, selective and covalent inhibitor of KRAS G12C.

BI-78D3, a competitive JNK inhibitor. IC50 of BI-78D3 is 280 nM that displays > 100 fold selectivity over p38α, and have no activity at mTOR and PI-3K.

N-Butyl α-D-fructofuranoside, extracted from the root barks of Ulmus davidiana var.

SSK1 is a senescent cell-killing and β-galactosidase-targeting precursor compound that activates phosphorylation levels of p38 MAPK in senescent cells.

Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12D

SKF-86002 is an effective inhibitor of p38 MAP kinase (IC50: 0.5-1 uM); inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50: 1 μM).

View and buy MRTX1133 from TargetMol.MRTX1133 is a potent, selective, and noncovalent inhibitor of KRAS G12D.

p38 MAPK-IN-1 is a novel selective p38 MAPK inhibitor with high potency, which reduces inflammatory responses by inhibiting LPS-induced TNF-α production.

Manassantin B is a potent inhibitor of NF-κB activation by the suppression of transciptional activity of RelA/p65 subunit of NF-κB.

N-Feruloyloctopamine is a natural product.

MEK-IN-4 is a MEK inhibitor that can be used to study inflammatory diseases and cancer.

SKLB646 is an orally active multitarget kinase inhibitor that exhibits potent suppression of several kinases. It demonstrates significant inhibitory effects on SRC and VEGFR2, with IC50 values of 0.002 μmol/L and 0.012 μmol/L, respectively. Additionally, SKLB646 shows notable inhibition of B-Raf and C-Raf, with IC50 values of 0.022 μmol/L and 0.019 μmol/L, respectively. The compound inhibits the activation of the SRC signaling pathway and blocks the MAPK signaling pathway by inhibiting Raf kinases. Furthermore, SKLB646 inhibits the proliferation, migration, and invasion of human umbilical vein endothelial cells (HUVEC), thereby suppressing tumor-induced angiogenesis. SKLB646 also displays significant anti-proliferative and anti-survival effects on triple-negative breast cancer (TNBC) cell lines.

Deoxyelephantopin: anti-inflammatory, hepatoprotective, wound healing, antitumor; blocks NF-κB, MAPK, PI3K/Akt, β-catenin pathways.

Opnurasib (JDQ-443) is an orally available and selective and potent covalent KRAS G12C inhibitor with antitumor activity for the study of advanced non-small

JNK peptide inhibitor. Mimics JIP-1 residues 153-163. Micromolar affinity, little effect on p38, ERK.

Isocryptotanshinone inhibits protein tyrosine phosphatase 1B (PTP1B) activity with 50% inhibitory concentration values of 56.1±6.3 μM, PTP1B acts as a negative

JNK-IN-7 (JNK inhibitor) is a selective JNK1/2/3 inhibitor (IC50: 1.54/1.99/0.75 nM).

Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently.

ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.

The BMS-582949 hydrochloride (BMS-582949 HCl) is a highly specific p38α MAPK inhibitor (IC50: 13 nM).

p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.

p38α inhibitor8 (Compound 1) demonstrates inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively.

Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.

RMC-0331 (RM-023) is an oral SOS1 inhibitor with potential to block RAS activation and anticancer properties.

Bongkrekic acid (Bongkrekic Acid (ammonium salt)) is a mitochondrial toxin secreted by Burkholderia cepacia that inhibits ANT.

BIX02189 is a potent and selective inhibitor of MEK5 and ERK5(IC50 : 1.5 nM and 59 nM).

Morusinol is a flavonoid extracted from the root bark of Morus alba. Morusinol has antiplatelet and anticancer activities, inhibits arterial thrombosis in vivo, and exerts antitumor activity by inducing autophagy, G2/M cell cycle blockade, inhibiting cell invasion and migration, and targeting the Ras/MEK/ERK pathway.

AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.

Enniatin B1, a Fusarium mycotoxin, crosses the blood-brain barrier and modulates ERK, NF-κB, and ACAT with an IC50 of 73 μM.

WYE-687 is a selective mTOR inhibitor (IC50: 7 nM), over 100x more selective for mTOR than PI3Kα/γ, affecting mTORC1/pS6K and mTORC2/P-AKT(S473).

Longdaysin is an inhibitor of CK1α and CK1δ (IC50s: 5.6/8.8 μM). It also can inhibit ERK2 (IC50: 52 μM).

WQ-C-401 is an orally active inhibitor of the platelet-derived growth factor receptor (PDGFR). It inhibits cell proliferation by blocking PDGFR auto-phosphorylation in a concentration-dependent manner, with EC50 values of 3.5 nM for PDGFRαY849 and 5.8 nM for PDGFRβY1021. Additionally, WQ-C-401 suppresses the proliferation and migration of PASMCs by inhibiting PDGF-BB-induced phosphorylation of ERK1/2, reduces collagen I synthesis, and increases α-SMA expression, thereby preventing pulmonary vascular remodeling. This compound shows promise for research in the field of pulmonary arterial hypertension.

RO4987655 (RG7167) is an orally active and highly selective MEK inhibitor (IC50: 5.2 nM for MEK1/MEK2).

B-Raf inhibitor 1 (B-Raf inhibitor 1) is a potent and selective B-Raf inhibitor.

KRAS G12D inhibitor 25 (Compound 148) acts as an inhibitor for KRAS G12C and HSP90α, displaying IC50 values of <0.1 μM and 0.1-1 μM respectively. Additionally, it suppresses the proliferation of MIA PaCa-2 and NCI-H358 cell lines, with EC50 values of <0.1 μM and 0.1-1 μM correspondingly. This compound also promotes the degradation of ERBB2, exhibiting a DC50 of 0.1-1 μM.

PROTAC BRAF-V600E degrader-1 (Compound 23) selectively induces degradation of BRAF-V600E but not wildtype BRAF.

EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.

Regorafénib N-oxyde M2 is an active metabolite of Regorafenib.

Patritumab (U3-1287), an anti-HER3 antibody, may inhibit tumor growth and cancer cell division in non-small cell lung cancer.

R1487 Hydrochloride (R1487 (Hydrochloride)) is an orally bioavailable and highly selective inhibitors of p38α.

KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].

TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively.

IQ3 inhibits JNK3 (Kd 66 nM), JNK1/2, NF-κB/AP1 in THP1-Blue cells (IC50 1.4 μM), and reduces TNF-α/IL-6 production.

trans-Zeatin ((E)-Zeatin) is the member of the plant growth hormone family known as cytokinins, which regulate cell division, development, and nutrient

TAK-715 is a p38 MAPK inhibitor for p38α.

Pepinh-TRIF TFA is a 30 aa peptide associated with the immune system that blocks TRIF signaling by interfering with TLR-TRIF interaction (TLR-TRIF interaction

MRTX0902 is an effective and high selective inhibitor of SOS1 with an IC50 of 46 nM and a Ki of 2 nM.

MLKL-IN-2 is an MLKL inhibitor with potential tumorigenic activity for the study of cellular necrosis-related diseases.

Plixorafenib (PLX8394) is an orally active inhibitor of the serine/threonine protein kinase B-Raf (BRAF) protein.Cost-effective and quality-assured.

SOS1-IN-16 (Comp 54) serves as a selective SOS1 inhibitor exhibiting an IC50 value of 7.2 nM and demonstrates inhibitory activity against CYP3A4 with an IC50 of

JTP10-△-TATi TFA is a selective inhibitor of JNK2 peptide (IC50: 92 nM), exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

ERK5-IN-1 is a potent ERK5 inhibitor (IC50: 87 nM). It also inhibits LRRK2[G2019S] (IC50: 26 nM).

Scio-323是一种可口服的 p38丝裂原活化蛋白(MAPK)激酶抑制剂。

KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.

SCH772984 is an ERK inhibitor and is highly selective and ATP-competitive. SCH772984 exhibits antitumor activity. Cost-effective and quality-assured.

L-(-)-Bornyl acetate, an enantiomer from hyssop oil, offers antifungal, skin-whitening, and antioxidant benefits, and reduces inflammation.

PROTAC K-Ras Degrader-3 is a PROTAC degrader targeting K-Ras, exhibiting a DC50 value of ≤ 1 nM against SW620 KRAS G12D and a GI50 value of ≤ 10 nM in inhibiting the growth of SW620 3D cells. It is used in cancer research.

Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.

FR 167653 sulfate, an orally active and selective inhibitor of p38 MAPK, is effective in treating inflammation, trauma, and ischemia-reperfusion injury in vivo. It acts as a potent suppressor of TNF-α and IL-1β production through specific inhibition of p38 MAPK activity.

LY3214996 (Temuterkib) is a potent oral ERK1/2 inhibitor with potential cancer-fighting properties.

Esculin sesquihydrate, a coumarin glucoside with fluorescent properties and a constituent of ash bark, improves cognitive deficits associated with experimental

Refametinib (RDEA119) (RDEA119, Bay 86-9766) is an effective, ATP non-competitive and specific inhibitor of MEK1/2 (IC50: 19/47 nM).